| Closed |
SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891) |
Local Bladder |
8/1/1987 |
7/1/1998 |
100% |
|
Published
|
| Closed |
SWOG-9312 |
Local Bladder |
10/1/1993 |
4/1/1998 |
100% |
|
Published
|
| Closed |
SWOG-8733 |
Local Bladder |
4/1/1988 |
2/15/1997 |
77% |
|
Published
|
| Closed |
S0121 |
Local Bladder |
11/15/2002 |
6/1/2005 |
9% |
|
|
| Closed |
S0219 |
Local Bladder |
1/1/2003 |
12/15/2006 |
81% |
|
Published
|
| Closed |
S0353 |
Local Bladder |
11/15/2006 |
10/15/2009 |
100% |
|
Published
|
| Closed |
S9921 |
Local Prostate |
10/15/1999 |
1/12/2007 |
72% |
|
|
| Closed |
SWOG-8794 |
Local Prostate |
8/15/1988 |
1/1/1997 |
100% |
|
Published
|
| Closed |
SWOG-9109 |
Local Prostate |
12/1/1993 |
10/15/1996 |
100% |
|
Published
|
| Closed |
S9615 |
Local Prostate |
10/15/1996 |
7/1/1998 |
2% |
|
|
| Closed |
S1400 |
Lung Master Protocol Advanced Squamous Cell NSCLC |
6/15/2014 |
|
|
|
|
| Closed |
S1403 |
Lung Ph II/III Stage IV NSCLC Afatinib+Cetuximab vs Afatinib |
3/25/2015 |
4/23/2018 |
29% |
|
|
| Closed |
S9925 |
Lung Repository |
9/1/2000 |
3/15/2010 |
|
|
|
| Closed |
S1400A |
Lung-MAP S1400A: Non-Match, MEDI4736 |
6/15/2014 |
11/18/2015 |
83% |
|
|
| Closed |
S1400B |
Lung-MAP S1400B: PI3K - GDC-0032 |
6/15/2014 |
12/12/2016 |
57% |
|
|
| Closed |
S1400C |
Lung-MAP S1400C: CDK4/6 - Palbociclib |
6/15/2014 |
|
91% |
|
|
| Closed |
S1400D |
Lung-MAP S1400D: FGFR - AZD4547 |
6/15/2014 |
10/31/2016 |
81% |
|
|
| Closed |
S1400E |
Lung-MAP S1400E: HGF - Rilotumumab plus Erlotinib vs. Erlotinib |
6/15/2014 |
11/25/2014 |
3% |
|
|
| Closed |
S1400F |
Lung-MAP S1400F: Non-Match-MEDI4736 and Tremelimumab |
10/2/2017 |
3/24/2020 |
51% |
|
|
| Closed |
S1400G |
Lung-MAP S1400G: HRRD - Talazoparib (BMN 673) |
2/7/2017 |
7/23/2018 |
85% |
|
|
